Navigation Links
VisEn Launches New OsteoSense(R) 800 and VivoTag(R) 800 Fluorescence Molecular Imaging Agents
Date:11/19/2009

BEDFORD, Mass., Nov. 19 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new OsteoSense® 800 imaging agent for targeting areas of bone turnover and microcalcification in vivo. The new 800 nm OsteoSense agent complements VisEn's OsteoSense 680 and 750 products, and is expected to further expand the utilization of this agent family in enabling in vivo detection, measurement and monitoring of skeletal changes in a wide range of disease states, including arthritis, osteoporosis, and cancer metastasis. In addition, VisEn has launched a new near infrared label, VivoTag 800® to add an additional wavelength channel to its current line of VivoTag fluorochromes which are used to label specific ligands of interest in a wide variety of in vivo and in vitro imaging applications. Both of the new 800 nm agents are well suited for imaging quantification on the VisEn FMT 2500(TM) LX quantitative tomography imaging system, which also has expanded wavelength capabilities to enable simultaneous imaging of up to four agents and biologies of interest in vivo.

VisEn's proprietary fluorescence imaging agents and labels are designed to provide the industry's broadest and most robust range of biologically-specific imaging readouts in vivo. VisEn now offers over 30+ different fluorescence molecular agents for imaging key disease-associated biologic targets, processes and pathways. VisEn agent brands include ProSense®, IntegriSense(TM), AngioSense(TM), OsteoSense®, Annexin-Vivo(TM), MMPSense(TM), Cat B FAST(TM), Cat K FAST(TM) and ReninSense(TM) FAST. VisEn also offers its specialized in vivo agent labeling platforms, including its proprietary VivoTag® fluorescence labeling dyes for custom agent development, and its NanoSpark
'/>"/>

SOURCE VisEn Medical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. VisEn Launches New Cat B 750 Fast(TM) Fluorescence Molecular Imaging Agent at American Heart Association Meeting
2. VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE
3. Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
4. TRACE Launches Compendium
5. Karmanos Cancer Institute Launches Company and Innovative Breast Imaging Tool
6. CareFusion Launches Knowledge Portal to Provide Actionable Information Across Product Platforms
7. Custom Spine Launches Pathway AVID and Regent ACP at NASS
8. Xanodyne Expands U.S. Sales Force and Launches Zipsor(TM) (diclofenac potassium) Liquid Filled Capsules
9. Cardio Vascular Medical Device Launches Corporate Website
10. Shire Re-Launches FOCUS, an Online, Personalized Patient Support Program for Adults with ADHD Taking Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII
11. Deloitte Recap Launches New Solution for Clinical Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013   Accuray Incorporated ... publication of study results involving hundreds of prostate ... System, the most widely used form of prostate ... 304 patients for a median of 5 years, ... that 97 percent of patients with low-risk and ...
(Date:5/21/2013)... Fla. , May 21, 2013  Janssen ... safety results from the global Phase 3 PROMISE ... inhibitor simeprevir (TMC435) led to sustained virologic response ... in 79 percent of treatment-experienced genotype 1 chronic ... including all stages of liver fibrosis, when administered ...
(Date:5/21/2013)... 21, 2013 Abaxis, Inc. (NasdaqGS: ABAX), a ... today that Martin Mulroy , chief ... Dental & Veterinary Conference on Wednesday, May 29, 2013 ... at Le Parker Meridien Hotel in New ... Abaxis develops, manufactures, markets and sells portable blood ...
Breaking Medicine Technology:New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 2New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2
... May 7 Patients treated with the ... at two years, according to interim results from ... a late-breaking clinical trial at the Society for ... Sessions. The prospective, single-arm study is ongoing to ...
... Inc. (NYSE: HRC ) today announced its fiscal 2010 third quarter dividend of ... 6, 2010 , and is payable on June 30, 2010 , to shareholders of record ... , , ABOUT ... Hill-Rom is a leading worldwide manufacturer and ...
Cached Medicine Technology:Drug-Eluting Peripheral Stent Continues to Show Positive Data at Two Years 2Drug-Eluting Peripheral Stent Continues to Show Positive Data at Two Years 3
(Date:5/21/2013)... The Special Olympics Missouri State Summer Games ... the state to Columbia. This state-level event takes place May ... and Columbia College, and at Hickman High School and Town ... kick off at 7:30 p.m. Friday, May 30 with the ... theme, the Parade of Athletes, the culmination of the statewide ...
(Date:5/21/2013)... Venice Beach, Calif. (PRWEB) May 21, 2013 ... to treating a dual diagnosis of Borderline Personality Disorder ... therapy that is proving to be successful for the ... Saturday, June 1, Alina Gorgorian, Ph.D., clinical director ... treatment in Los Angeles, will provide attendees of ...
(Date:5/21/2013)... autism showed significant improvement after six months of simple ... scents, spoons and sponges, according to UC Irvine neurobiologists. ... enrichment led to notable gains in male subjects between ... in Behavioral Neuroscience . , Study co-authors Cynthia ... one of two groups, balanced for age and autism ...
(Date:5/21/2013)... 2013 STAR (Sensory Therapies And ... with sensory challenges and the Sensory Processing Disorder ... and advocacy of Sensory Processing Disorder present Stumbling Blocks ... Improve Quality of Life, a two-hour lecture presented by ... , Learn a method that can aid in ...
(Date:5/21/2013)... Chicago, IL (PRWEB) May 21, 2013 ... business process integration solutions, today announced it is the ... by analyst firm 451 Research. The report, “Adeptia Bets ... in-depth review of the company, its strategy, products, pricing, ... are in need of a framework for integration and ...
Breaking Medicine News(10 mins):Health News:Special Olympics Missouri Athletes Ready to Show Off Skills in Columbia 2Health News:Special Olympics Missouri Athletes Ready to Show Off Skills in Columbia 3Health News:Clearview Treatment Programs Clinical Director to Present on DBT and Substance Abuse at WCSAD 2Health News:Clearview Treatment Programs Clinical Director to Present on DBT and Substance Abuse at WCSAD 3Health News:Enrichment therapy effective among children with autism, UCI study finds 2Health News:STAR Center and SPD Foundation Present a Lecture on Teens and Adults with Sensory Processing Disorder 2Health News:STAR Center and SPD Foundation Present a Lecture on Teens and Adults with Sensory Processing Disorder 3Health News:Adeptia Featured in Recent 451 Research Impact Report 2
... common condition, researchers say , TUESDAY, March 30 (HealthDay News) ... deep vein thrombosis, it is most likely to occur on ... researchers have found. , Dr. Wee-Shian Chan of Women,s ... review, said in a news release that the clots most ...
... Osmosis Day ... business with more than 200,000 of the unique healing bath treatments delivered in a Japanese ... Freestone, CA (PRWEB) ... chicken coop, Osmosis, a day spa in Sonoma County California , has delivered more ...
... from arthritis and osteoporosis to broken bones that won,t ... a key molecular player to keep stem cells in ... makes treatment with the cells in the future more ... the cells, known as mesenchymal (pronounced meh-ZINK-a-mill) stem cells, ...
... and the American Society of Hematology (ASH) have selected ... EHA-ASH Research Exchange Award, which serves to strengthen ties ... Ingmar Bruns is a resident physician and research scientist ... at the University of Dsseldorf in Germany. After graduating ...
... ... Serve Spanish-Speaking Patients , ... (PRWEB) March 30, 2010 -- The HealthLinkRx Institute has announced news dates ... sessions of the Institute’s “Therapy in Spanish” class will be offered in Austin, TX ...
... , TUESDAY, March 30 (HealthDay News) -- Researchers have ... be linked to autism disorders. , "To our knowledge, ... of association between these important genes in brain connections ... of the Wellcome Trust Center for Human Genetics at ...
Cached Medicine News:Health News:California Day Spa - Osmosis Celebrates 25th Anniversary With Over 200,000 Cedar Enzyme Baths Given 2Health News:California Day Spa - Osmosis Celebrates 25th Anniversary With Over 200,000 Cedar Enzyme Baths Given 3Health News:Promoting healing by keeping skeletal stem cells 'young' 2Health News:Promoting healing by keeping skeletal stem cells 'young' 3Health News:European hematologist receives award to conduct research in US 2Health News:HealthLinkRx Announces Classes in Spanish for Occupational and Physical Therapists 2
... Olympus has pioneered the ... neurosurgical imaging system, an innovative ... be more efficient and less ... consists of the OME-7000 surgical ...
The Leica MS1 F/MC1 F is designed to mount on the ceiling with a high degree of mobility. Its unique and patented suspension concept assures a superior stability and a perfect and steady microscope i...
... SheerVision surgical magnifying loupes are ... quality optics which provide the healthcare ... and greater depth of field. Each ... in a fully lined wooden box ...
... Advantage delivers higher magnification for advanced surgical ... image, even at the highest magnification. 3.5x, ... and precise color rendition is ideal for ... anti-reflective coating produce a superior image. The ...
Medicine Products: